KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 73 filers reported holding KINNATE BIOPHARMA INC in Q4 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $11,213,621 | -53.8% | 8,009,729 | 0.0% | 0.24% | -45.9% |
Q2 2023 | $24,269,479 | -24.5% | 8,009,729 | +55.7% | 0.44% | -30.3% |
Q1 2023 | $32,147,681 | +30.3% | 5,143,629 | +27.2% | 0.63% | +33.7% |
Q4 2022 | $24,666,137 | -49.0% | 4,043,629 | 0.0% | 0.47% | -47.4% |
Q3 2022 | $48,321,000 | -5.2% | 4,043,629 | 0.0% | 0.90% | -2.9% |
Q2 2022 | $50,990,000 | +12.0% | 4,043,629 | 0.0% | 0.92% | +25.2% |
Q1 2022 | $45,531,000 | -33.2% | 4,043,629 | +5.1% | 0.74% | -15.8% |
Q4 2021 | $68,185,000 | -23.0% | 3,847,929 | 0.0% | 0.88% | -9.9% |
Q3 2021 | $88,579,000 | -1.1% | 3,847,929 | 0.0% | 0.97% | +7.4% |
Q2 2021 | $89,580,000 | -25.3% | 3,847,929 | 0.0% | 0.91% | -19.2% |
Q1 2021 | $119,901,000 | -21.7% | 3,847,929 | 0.0% | 1.12% | -16.3% |
Q4 2020 | $153,071,000 | – | 3,847,929 | – | 1.34% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 3,525,957 | $4,936,340 | 7.88% |
Foresite Capital Management IV, LLC | 9,671,643 | $13,540,300 | 7.52% |
Vida Ventures Advisors, LLC | 2,207,772 | $3,090,881 | 4.78% |
Lynx1 Capital Management LP | 1,997,006 | $2,795,808 | 1.85% |
Nextech Invest Ltd. | 2,329,480 | $3,261,272 | 0.99% |
Orbimed Advisors | 8,009,729 | $11,213,621 | 0.24% |
Novo Holdings A/S | 815,707 | $1,141,990 | 0.08% |
DAFNA Capital Management LLC | 105,179 | $147,251 | 0.05% |
GSA CAPITAL PARTNERS LLP | 374,291 | $524 | 0.04% |
Rock Springs Capital Management LP | 405,811 | $568,135 | 0.02% |